EGFR and glioblastoma: The multivariate analysis, considering EGFR amplification, PTEN deletion and MGMT methylation and controlling for age, gender and treatment, validated the role of PTEN deletion (Hazard Ratio (HR) =0.65; 95% CI 0.43–0.99) and MGMT promoter methylation (HR = 0.61; 95% CI 0.42–0.88) as independent factors of prognosis in GBM IDH-wildtype.